Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation
NCT ID: NCT04811326
Last Updated: 2023-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
150 participants
INTERVENTIONAL
2021-01-13
2024-03-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.
NCT05513924
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
NCT03199664
Combined Effect of Acitretin and Narrow Band Ultraviolet B on Vitiligo Repigmentation
NCT04245319
Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases.
NCT05316987
Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo
NCT03358082
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NB-UVB radiation
will expose to 2 sessions/week of NB-UVB radiation, for 3 months.
NB-UVB
radiation
Latanoprost
latanoprost 0.005%, will be applied after microneedling, by using 1.5-2 mm needle length dermapen, of vitiligenous patches. The procedure will be repeated once weekly for 3 months (12 sessions).
Latanoprost
eye drops
latanoprost + NB-UVB
(latanoprost + NB-UVB group): latanoprost 0.005%, will be applied after microneedling of vitiligenous patches in the same day of NB-UVB sessions in the same manner of group 2.
NB-UVB
radiation
Latanoprost
eye drops
healthy individuals
healthy individuals as control group
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NB-UVB
radiation
Latanoprost
eye drops
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnancy and lactation.
* Infections
* Patients with other autoimmune diseases.
* Patients with chronic diseases: cardiac diseases, hepatic disorders, hematologic disease, chronic renal failure or malignancies.
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shaimaa Fawzy Abdel-rady Abdel-latif
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shaimaa Fawzy Abdel-rady Abdel-latif
investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Moustafa A El Taieb, prof.
Role: STUDY_CHAIR
Prof. and Head of Dermatology, Venereology and Andrology department, Aswan University, Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
faculty of medicine, Aswan University
Aswān, Aswan Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
504/1/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.